Inhibition of Oxidized Low-density Lipoprotein-induced Apoptosis in Endothelial Cells by Nitric Oxide

PEROXYL RADICAL SCAVENGING AS AN ANTIAPOPTOTIC MECHANISM*

Srigiridhar KotamrajuDagger , Neil HoggDagger , Joy JosephDagger , Larry K. Keefer§, and B. KalyanaramanDagger

From the Dagger  Biophysics Research Institute and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 and the § National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702

Received for publication, December 27, 2000, and in revised form, February 1, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proatherogenic oxidized low-density lipoprotein (oxLDL) induces endothelial apoptosis. We investigated the anti-apoptotic effects of intracellular and extracellular nitric oxide (·NO) donors, iron chelators, cell-permeable superoxide dismutase (SOD), glutathione peroxidase mimetics, and nitrone spin traps. Peroxynitrite (ONOO-)-modified oxLDL induced endothelial apoptosis was measured by DNA fragmentation, TUNEL assay, and caspase-3 activation. Results indicated the following: (i) the lipid fraction of oxLDL was primarily responsible for endothelial apoptosis. (ii) Endothelial apoptosis was potently inhibited by ·NO donors and lipophilic phenolic antioxidants. OxLDL severely depleted Bcl-2 levels in endothelial cells and ·NO donors restored Bcl-2 protein in oxLDL-treated cells. (iii) The pretreatment of a lipid fraction derived from oxLDL with sodium borohydride or potassium iodide completely abrogated apoptosis in endothelial cells, suggesting that lipid hydroperoxides induce apoptosis. (iv) Metalloporphyrins dramatically inhibited oxLDL-induced apoptosis in endothelial cells. Neither S-nitrosation of caspase-3 nor induction of Hsp70 appeared to play a significant role in the antiapoptotic mechanism of ·NO in oxLDL-induced endothelial apoptosis. We propose that cellular lipid peroxyl radicals or lipid hydroperoxides induce an apoptotic signaling cascade in endothelial cells exposed to oxLDL, and that ·NO inhibits apoptosis by scavenging cellular lipid peroxyl radicals.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ample evidence supports the notion that oxidatively modified low-density lipoprotein (oxLDL)1 plays a key role in the onset of atherogenic processes (1-8). Endothelial injury is considered to be one of the earliest atherogenic events (9-11). The cytotoxic effects of oxLDL are well established (12-15). Endothelial injury plays a prominent role in the increased adherence of monocytes and their migration into the subendothelial space of blood vessels (16-18). The adhesion of monocytes to the endothelium is a key atherogenic process (9, 10). Recently it has been shown that the activation of the cellular suicide pathway of the endothelial cell may be crucial to the development of atherosclerosis (19-26). Although the exact mechanism of oxLDL-induced apoptosis in endothelial cells remains unknown, published reports suggest a role for free radical intermediates (27-31). It has also been reported that the up-regulation of endothelial nitric-oxide synthase (eNOS) and copper-zinc superoxide dismutase and/or manganese superoxide dismutase protects endothelial cells against oxLDL-induced apoptosis (32). Collectively, these reports reveal an intriguing link between oxLDL, apoptosis, and nitric oxide (·NO)/superoxide (O&cjs1138;2) interaction in endothelial cells.

Nitric oxide has been reported to have a dual effect on cell-dependent LDL oxidation (33). ·NO acts as a pro-oxidant in the presence of O&cjs1138;2 and an antioxidant in the presence of lipid peroxyl radical (34-36). The reaction between ·NO and O&cjs1138;2 to form peroxynitrite (ONOO-) is one of the most facile radical-radical recombination reactions in free radical biology (37, 38). ·NO also reacts with lipid peroxyl radical (LOO·) at a nearly diffusion-controlled rate (k = 1-3 × 109 M-1 s-1) (39). This rate constant is ~107 times greater than that reported for the reaction between LOO· and unsaturated lipid, and 104 times greater than the rate constant for the reaction of LOO· with alpha -tocopherol (36). Thus, ·NO can act as a potent chain-breaking antioxidant. Consequently, the reaction between ·NO and O&cjs1138;2 has the combined effect of removing an antioxidant such as ·NO, and generating the prooxidant, ONOO-. The role of these reactions in regulating downstream apoptosis cell signaling has not been fully investigated.

In vivo immunohistochemical studies in atherosclerotic tissues indicate the presence of oxidation and nitration marker products (i.e. lipid hydroperoxides and nitrotyrosine) that are diagnostic for reactive oxygen and nitrogen species (23, 37-40). In this study we tested the hypothesis that the propagation of lipid peroxidation is primarily responsible for oxLDL-induced apoptosis. Therefore, we investigated the effects of extracellular and intracellular ·NO donors (NONOates), cell-permeable SOD mimetics and ONOO- scavengers (MnTBAP and FeTBAP), a cell-permeable mimetic of glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase (ebselen), lipophilic phenolic antioxidant (probucol), and a nitrone spin trap alpha -phenyl-tert-butyl nitrone (PBN) (Fig. 1) on endothelial apoptosis induced by oxLDL. Results show that ·NO inhibits oxLDL-induced apoptosis as do MnTBAP/FeTBAP, ebselen, Probucol, and PBN. These structurally diverse antioxidants share a common mechanism that is their ability to inhibit the propagation of lipid peroxidation. Therefore, we propose that the major antiapoptotic mechanism of ·NO involves peroxyl radical scavenging.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Structure of compounds.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) and PBN were obtained from Sigma. PBN was also obtained from the Oklahoma Medical Research Foundation Spin Trap Source as a gift from Dr. Ronald Mason (NIEHS, National Institutes of Health, Research Triangle Park, NC). Mn(III)-tetrakis(4-benzoic acid) porphyrin (MnTBAP), FeTBAP, and S-nitrosoglutathione (GSNO) were synthesized according to the published methods (42, 43). Probucol was purchased from Sigma. Diethylenetriamine NONOate (DETA/NO) was obtained from Cayman Chemical Co. Anti-Hsp70 antibody and hamster anti-human Bcl-2 antibody and diethylenetriaminepentaacetic acid (DTPA) were purchased from Pharmingen.

Cell Culture-- Bovine aortic endothelial cells (BAEC) harvested from thoracic aortas were maintained (37 °C, 5% CO2) in Dulbecco's modified eagles medium (1 g/liter of glucose, Life Technologies, Inc.) containing 15% fetal bovine serum (Sigma) with antibiotics. Cells used in this study were between passages 5 and 10.

Human umbilical vein endothelial cells were obtained from Clonetics and cultured in endothelial basal medium (Clonetics) containing 2% fetal bovine serum, 10 ng/ml human recombinant epidermal growth factor, 1 µg/ml hydrocortisone, 50 µg/ml gentamycin, 50 ng/ml amphotericin-B, and 3 mg/ml bovine brain extract. Cells cultured between passages 2 and 4 were used in this study.

Preparation of LDL and LDL Lipid Extraction-- LDL was isolated by sequential ultracentrifugation (d = 1.019-1.063) from freshly drawn, normolipidemic human plasma to which EDTA was added (44). LDL was oxidized by adding ONOO- (1 mM). In control experiments, LDL was added to a phosphate buffer (pH 7.4, 100 mM) containing pre-decomposed ONOO-. Medium containing 150 µg of the modified LDL was extracted by adding 2 volumes of ice-cold methanol followed by 2 volumes of chloroform (45). The mixture was centrifuged at 1800 × g for 10 min to separate the phases. The lipid phase was carefully removed and evaporated under a stream of nitrogen and re-dissolved in a minimum volume of methanol.

Treatment of BAEC with OxLDL-- For all treatments, cells were washed twice with Dulbecco's phosphate-buffered saline and incubated with serum-free Dulbecco's modified Eagle's medium in the presence or absence of reagents. Either native or oxidized LDL was added to a final concentration of 150 µg of LDL protein/ml.

Quantification of DNA Fragmentation by Gel Electrophoresis-- DNA was isolated from BAEC. Culture medium was removed and centrifuged at 3000 × g for 5 min to collect any detached cells. Adherent cells were lysed with a hypotonic lysis buffer (10 mM Tris-HCl, 10 mM EDTA, 0.5% Triton X-100) and then pooled with the pellet made up of detached cells. After incubation at 4 °C for 15 min, lysates were incubated with 10 µl of 10 mg/ml RNase A for 1 h at 37 °C followed by 10 µl of 20 mg/ml proteinase K for 2 h at 50 °C. DNA was extracted using chloroform:phenol:isoamyl alcohol (25:24:1). It was then precipitated overnight with 1 volume of isopropyl alcohol at -20 °C, electrophoresed on 2% agarose gel, and then visualized under UV light after staining with ethidium bromide.

Terminal Deoxynucleotidyltransferase-mediated Nick-end Labeling Assay-- Apoptosis was detected in BAEC's using terminal deoxynucleotidyltransferase-mediated nick-end labeling (TUNEL) assay (46). Labeling of 3' free hydroxyl ends of the fragmented DNA with fluorescein-dUTP, was catalyzed by terminal deoxynucleotidyltransferase (TdT) using a commercially available kit (ApoAlert, CLONTECH) following the manufacturer's directions. The areas of apoptotic cells were then detected by fluorescence microscopy equipped with rhodamine (for propidium iodide staining) and fluorescein isothiocyanate filters. The quantification of apoptosis was performed using Sigma Scan 5.0 Image Analysis package. Propidium iodide-stained cells (which represents the total number) were counted under rhodamine filter and the apoptotic (TUNEL positive) cells were counted under fluorescein isothiocyanate filter. Percentage of apoptosis was calculated from the ratio of these two measurements.

Caspase-3 Enzyme Activity-- Cells were washed after treating with appropriate drugs with phosphate-buffered saline and resuspended in 50 µl of chilled lysis buffer (Caspase-3 assay kit, CLONTECH) and incubated on ice for 10 min. The cell lysates were centrifuged in a microcentrifuge at 12,000 rpm for 3 min at 4 °C to precipitate cellular debris.

To confirm the correlation between protease activity and signal detection, we performed a control reaction as follows. An induced sample was incubated with 0.5 µl of 1 mM DEVD-fmk (caspase inhibitor) at 37 °C for 30 min during which time the other tubes consisting of lysis buffer were kept on ice. Subsequently, 50 µl of reaction buffer (containing 7 µl of 1 mM dithiothreitol/ml of reaction buffer) was added, followed by the addition of 5 µl of 1 mM conjugated substrate (DEVD-p-nitroanilide, 50 µM final concentration) to each sample. After incubating at 37 °C for 1 h, absorptions were monitored at 405 nm in a spectrophotometer (46).

Analysis of Hsp70 and Bcl-2 Protein Levels-- BAEC were washed with ice-cold phosphate-buffered saline and resuspended in 100 µl of RIPA buffer (20 mM Tris-HCl, pH 7.4, 2.5 mM EDTA, 1% Triton-X 100, 1% sodium deoxycholate, 1% SDS, 100 mM NaCl, 100 mM sodium fluoride. To a 10-ml solution of the above, the following agents were added: 1 mM sodium vanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin inhibitors.) Cells were homogenized by passing the suspension through a 25-gauge needle (10 strokes). The lysate was centrifuged at 750 × g for 10 min at 4 °C to pellet out the nuclei. The remaining supernatant was centrifuged for 15 min at 12,000 × g. Protein was determined with the Lowry method (47), and 25 µg were used for the Western blot analysis. Proteins were resolved on polyacrylamide gels (8% for Hsp70 and 18% for Bcl-2) and blotted onto nitrocellulose membranes. Sheets were washed twice with TBS (140 mM NaCl, 50 mM Tris-HCl, pH 7.2) containing 0.1% Tween 20 before blocking the nonspecific binding with TBS, 5% skim milk, 1% fetal calf serum. Filters were incubated with either mouse anti-Hsp70 antibody (Pharmingen) or hamster anti-human Bcl-2 antibody (Pharmingen) 1 µg/ml in TBS, 2% skim milk, 0.7% fetal calf serum for 2 h at room temperature. Sheets were washed 5 times and detected by horseradish peroxidase-conjugated goat anti-mouse monoclonal antibody (1:1000) for Hsp70 and anti-hamster IgG (1:1000) for Bcl-2 for 1.5 h at room temperature using the ECL method (Amersham Pharmacia Biotech).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Effect of Small Molecular Weight Peroxyl Radical Scavengers, Cell-permeable Antioxidant Enzyme Mimetics, and Antioxidant Enzymes on OxLDL-induced Apoptosis-- After incubating BAEC for 24 h with native LDL, no DNA fragmentation was observed (Fig. 2A, lane 2). However, if the LDL was pre-oxidized, either with copper (II) sulfate (100 µM) or with ONOO- (1 mM), significant DNA laddering occurred (Fig. 2A, lanes 3 and 4). DNA laddering did not occur in the presence of decomposed ONOO- (not shown). In addition, the dialysis of LDL after treatment with ONOO- did not alter the ability of LDL to fragment cellular DNA (not shown). This indicates that ONOO- caused the oxidation of a component of LDL to an intermediate or product that stimulated DNA fragmentation, and that this intermediate remained associated with the LDL particle during dialysis. This suggests that apoptosis is not caused by a decomposition product of ONOO-, nor by a low-molecular weight, soluble, LDL oxidation product, such as malondialdehyde or 4-hydroxynonenal in cells exposed to ONOO--modified LDL. OxLDL-induced DNA laddering was significantly inhibited in the presence of Probucol (Fig. 2B, lane 4), nitrone trap, PBN (Fig. 2B, lane 6), and metalloporphyrin antioxidant, FeTBAP (Fig. 2B, lane 7).


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of oxLDL on DNA fragmentation in BAEC and the effect of free radical scavengers. BAEC were incubated for 16 h with and without additions. Cells were harvested and DNA was extracted for fragmentation analysis. A, the lanes correspond to: 1, cells alone; 2, native LDL (150 µg/ml); 3, copper (II)-modified oxLDL; and 4, ONOO--modified oxLDL. B, the lanes correspond to: 1, native LDL; 2, oxLDL (150 µg/ml); and oxLDL with the addition of: 3, probucol (10 µM); 4, probucol (100 µM); 5, PBN (100 µM); 6, PBN (1 mM); and 7, FeTBAP (10 µM).

In addition to DNA fragmentation, the effect of oxLDL on the activation of caspase-3 was also investigated. Caspase-3, one of the downstream members of this enzyme family, is activated by proteolysis and is considered to be a committed step in several apoptotic pathways (46). As shown in Table I, native LDL did not enhance caspase-3 activity, whereas oxLDL stimulated caspase-3 activity by ~5-fold. This suggests that the oxLDL-mediated apoptosis acts through the activation of caspase-3.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of antioxidants and antioxidant enzymes on oxLDL-induced caspase-3 activation
OxLDL was prepared by adding ONOO- (100 µM) to native LDL (150 µg/ml) in 50 mM phosphate buffer after 2 h, the LDL particle was extensively dialyzed to remove excess ONOO- and other oxidants. BAEC were treated with oxLDL for 16 h. Values are mean ± S.D. of three independent experiments.

In order to examine the mechanism of oxLDL-induced apoptosis, the effects of a range of antioxidants were examined (Table I). These compounds were chosen based on their wide range of targets and on their differential compartmentalization. BHT, a peroxyl radical scavenger, and DTPA, a metal chelator, both inhibited caspase-3 activation. This suggests that metal ion-dependent lipid peroxidation propagation reactions, involving the breakdown of LOOH and the formation of LO·/LOO· are important steps in mediating the apoptotic cascade. Ebselen, a selenium-containing glutathione peroxidase mimetic abolished the activation of oxLDL-mediated caspase-3. Ebselen is able to access both the intracellular and extracellular compartments and cause degradation of both intracellular and extracellular hydroperoxides (48). However, the availability of thiols (which are required to mediate ebselen-dependent peroxide decomposition) may be limited in the extracellular environment. The antioxidant enzymes, SOD and catalase, had little effect on caspase-3 activation. As the actions of these enzymes are limited to the extracellular environment, this observation implies that neither superoxide nor hydrogen peroxide present in the extracellular compartment is involved in the initiation of apoptosis. In contrast, the cell-permeable metalloporphyrin SOD mimetics, MnTBAP and FeTBAP, inhibited caspase-3 activation to almost control levels (49-51). It is noteworthy that FeTBAP was effective at a 10-fold lower concentration than MnTBAP. Although the exact reasons for this differential effect are not understood, it is consistent with the increased activity of FeTBAP as a catalyst of superoxide dismutation or ONOO- decomposition. The metal-free porphyrin, TBAP, had little effect on caspase-3 activation. Nitrone trap caused a 70% inhibition in caspase-3 activation as did desferral, a chelator of redox-active iron (Table I). The present data suggest that oxLDL-induced intracellular superoxide or chain-propagating lipid peroxyl radicals mediate the intracellular signal transduction mechanism leading to caspase-3 activation.

The Effect of Extracellular and Intracellular Nitric Oxide Donors on OxLDL-induced Apoptosis-- We previously reported that ·NO donor compounds and S-nitrosothiols will inhibit the toxicity of oxLDL to endothelial cells in culture (52). We ascribed this effect to the ability of ·NO to scavenge LOO· radicals and so to prevent lipid hydroperoxide-mediated oxidation of the membranes (35, 36, 53). In the present study we examined whether nitric oxide donors and S-nitrosothiols could inhibit oxLDL-mediated apoptosis. Fig. 3 confirms the pro-apoptotic effect of oxLDL on BAEC, as treatment of cells with ONOO--modified oxLDL for 18 h results in significant TUNEL positive staining (Fig. 3A). Both the nitric oxide donor, DETA/NO, and the S-nitrosothiol, GSNO, significantly prevented the TUNEL positive staining (Fig. 3, C and D), suggesting that these compounds inhibited DNA fragmentation. These results are shown quantitatively in Fig. 3E.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of NO donors on DNA fragmentation. A, BAEC were treated for 16 h with native LDL (150 µg/ml); B, with oxLDL (150 µg/ml); C, with oxLDL and DETA/NO (100 µM); D, with oxLDL and 1 mM GSNO. Cells were harvested, stained for TUNEL-positive cells, and examined by fluorescence microscopy, and E, the percent apoptosis was quantitated by image analysis.

Caspase-3 is a cysteine protease that is synthesized in an inactive "pro" form. The apoptotic cascade results in the proteolytic activation of pro-caspase to generate active caspase-3. It has been demonstrated that caspase-3 can be inactivated by S-nitrosation of the active site thiol (54, 55). In addition to DNA fragmentation, ONOO--treated LDL caused an almost 5-fold induction in caspase-3 activity, as measured by following the formation of p-nitroanilide (Table I). Both DETA/NO and GSNO substantially inhibited caspase-3 activation (Fig. 4A). This inhibition of caspase activity was not due to S-nitrosation as the addition of dithiothreitol, which will remove any S-nitrosothiols, did not alter the caspase activity (data not shown).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4.   The effect of NO donors on oxLDL-induced caspase activation. A, the effects of native LDL (150 µg/ml), oxLDL (150 µg/ml), GSNO (1 mM), and DETA/NO (100 µM) on caspase-3 activity measured in BAEC. Cells were treated 16 h with the respective agents and incubated. B, time course of caspase-3 activation induced by oxLDL (150 µg/ml) in the presence and absence of 100 µM DETA/NO.

The time course of caspase activation by oxLDL is shown in Fig. 4B. Caspase-3 activity was stimulated between 4 and 8 h after adding oxLDL, and remained high for up to 24 h. In the presence of an ·NO donor, DETA/NO, only a slight increase in caspase-3 activity was observed over 24 h, but the large increase in activity between 4 and 8 h was abolished. DETA/NO, an extracellular ·NO donor, spontaneously decays within the cell culture medium. Consequently, ·NO is generated in the solution above the cells. To examine the effect of intracellular ·NO production, we used a novel set of compounds that pass through the cell membrane and are de-esterified inside the cell to give the active ·NO donor (56). Consequently, ·NO released from these compounds is generated within the intracellular environment. As shown in Fig. 5, these compounds were able to suppress oxLDL-mediated caspase-3 activation at concentrations that were 50-100-fold lower than the extracellular ·NO donor, DETA/NO. With 1 µM of these esterase-sensitive intracellular ·NO donors, robust inhibition was observed, whereas 5 µM AcOM-DEA/NO or AcOM-PYRRO/NO completely suppressed caspase-3 activation (Fig. 5).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   The effect of cell-permeable ·NO donors on oxLDL-induced caspase 3 activation. BAEC were treated with ONOO--oxLDL (150 µg/ml) for 16 h in the presence and absence of cell-permeable ·NO donors. For structures of ·NO donors, see Fig. 1.

To determine the component of the LDL particle that was responsible for apoptosis, we isolated the lipid component of oxidized and native LDL and examined the effects of the extracts on caspase-3 activation. As shown in Fig. 6, exposure of cells to the lipid extract of native LDL resulted in only a minor increase in caspase activity, which was inhibited by DETA/NO and GSNO. In contrast, the lipid fraction of oxLDL caused a significant activation of caspase-3 activity to a level almost equivalent to that observed with whole oxLDL particle. This indicates that the lipid component of the LDL particle is largely responsible for the activation of caspase-3. Both DETA/NO and GSNO inhibited caspase-3 activation by oxLDL extract, indicating that the pro-apoptotic intermediate, that is inhibited by ·NO, is present in the lipid component of oxLDL. The influence of lipid hydroperoxides on caspase-3 activation was assessed by reducing the peroxides to alcohols using potassium iodide or sodium borohydride. Treatment of oxLDL lipid extract with these agents, before addition to the cells, ablated the ability of this lipid mixture to activate caspase-3 (Fig. 6). These results suggest that the lipid hydroperoxide component of oxLDL is responsible for caspase activation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   The effect of ·NO donors and reductants on caspase-3 activation induced by LDL lipid extracts. BAEC were treated with lipid extracts of oxLDL and native LDL in the presence and absence of DETA/NO (100 µM), GSNO (500 µM), KI (1 mM), and NaBH4 (1 mM). After 16 h, caspase activity was measured.

It has been previously reported that 7-ketocholesterol (7-KC), a known oxidation product of cholesterol, is pro-apoptotic (57-59). In Fig. 7, the effect of oxLDL was compared with 7-KC. Both agents enhanced caspase-3 activation, whereas only oxLDL-dependent caspase-3 activation was inhibited by DETA/NO. This suggests that 7-KC enhances caspase-3 activity, and hence apoptosis, by a mechanism that is distinct from oxLDL. However, the level of 7-KC (e.g. 40-100 µg/ml), required to promote apoptosis far exceeds the levels of 7-KC expected to be present in oxLDL used in these experiments.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   The effect of ·NO donor on 7-ketocholesterol-induced apoptosis. BAEC were treated with 10, 40, and 100 µg/ml 7-KC for 16 h in the presence and absence of DETA/NO (100 µM). For the sake of comparison, data using oxLDL alone and oxLDL in the presence of DETA/NO are also included.

The Effect of Hsp70 and Bcl-2 Induction on OxLDL-induced Apoptosis-- It has previously been reported that the anti-apoptotic effects of ·NO can be correlated to the stimulation of heat shock protein 70 (Hsp-70) synthesis (60, 61). Fig. 8A demonstrates that control cells showed little or no Hsp-70 content as determined by the Western blot analysis. However, when cells with DETA/NO, GSNO, or native LDL were incubated, Hsp-70 synthesis was induced. We further observed that oxLDL induced a much lower level of protein expression, which was increased in the presence of DETA/NO or GSNO. This data suggested an inverse correlation between Hsp-70 content and caspase-3 activation. To examine if preinduction of Hsp-70 could protect against oxLDL, we pretreated cells for 6 h with DETA/NO, GSNO, or native LDL and then exposed these cells to oxLDL. After 16 h these cells showed a robust expression of Hsp-70 with a high level of caspase activation (Fig. 8B). Under these conditions we found no correlation between caspase-3 activation and Hsp-70 induction. Therefore the induction of Hsp-70 is not inhibitory to oxLDL-mediated apoptosis, but is a parallel process that is stimulated by exposure of cells to DETA/NO, GSNO, or native LDL.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   The effect of Hsp70 induction on oxLDL-induced apoptosis in BAEC. A, cells were treated with 100 µM DETA/NO or 500 µM GSNO for 16 h in the absence and presence of LDL (150 µg/ml). Increase in Hsp70 expression was shown by the Western blot analysis. The lanes correspond to: 1, control; 2, DETA/NO; 3, GSNO; 4, oxLDL; 5, oxLDL and GSNO; 6, oxLDL and DETA/NO; and 7, nLDL. B, cells were treated with ·NO donors for 6 h then cells were washed free of ·NO donors and treated with oxLDL for 16 h. Caspase-3 activity was measured subsequently.

Results described in Fig. 8B demonstrate that DETA/NO and GSNO must be present at the same time as the oxLDL in order to prevent caspase activation. Hence, these agents affect the cell directly and instantly rather than through the sustained and mediated induction of antioxidant or antiapoptotic enzymes in the system.

In search of the molecular mechanism(s) responsible for the protective effects, we also measured the relative amounts of Bcl-2 protein as described in Fig. 9. Bcl-2 was significantly inhibited in the oxLDL-treated group (62). OxLDL-induced depletion of Bcl-2 was restored in the presence of ·NO donors and other antioxidants (Fig. 9). Similar results were obtained using human umbilical vein endothelial cells (data not shown). This indicates that the antiapoptotic effect of ·NO in human umbilical vein endothelial cells is likely to be mediated by the same mechanism as occurs in BAEC.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 9.   The effect ·NO donors and antioxidants on Bcl-2 levels during oxLDL-induced apoptosis. BAEC were treated with: 1, no treatment; 2, nLDL (150 µg/ml); 3, oxLDL (150 µg/ml); 4, oxLDL + 500 µM GSNO; 5, oxLDL + 100 µM DETA/NO; 6, oxLDL + 1 mM PBN; and 7, oxLDL + 100 µM MnTBAP for 16 h and Bcl-2 protein levels were measured by the Western analysis.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mechanism of OxLDL-induced Endothelial Apoptosis-- The pathophysiological effects of oxLDL in vascular cells have previously been investigated using oxLDL as a whole (1-10). It is also well known that cells are more vulnerable to oxLDL-induced toxicity if serum or other proteins are excluded from the media. Reports also indicate that oxLDL-induced endothelial apoptosis is markedly diminished in the presence of added serum (63). As our objective was to elucidate the mechanism of oxLDL-induced cellular injury, experiments were performed in the absence of serum.

The individual components of oxLDL responsible for mediating apoptosis are not known. OxLDL is a mixture of several cytotoxic components consisting of lipid hydroperoxides (e.g. 9- and 13-hydroperoxyoctadecadienoic acid, cholesteryl hydroperoxyoctadecadienoate, aldehydes such as 4-hydroxynonenal and malondialdehyde, and oxysterols (7-ketocholesterol, 7beta -hydroxycholesterol)). Individually these components are potent inducers of apoptosis in several cell types including bovine and human endothelial cells. In the present work, we have shown that the lipid extract of oxLDL containing lipid hydroperoxides induces endothelial apoptosis in BAEC or human umbilical vein endothelial cells exposed to ONOO--modified LDL. Possible proapoptotic candidates present in ONOO--modified LDL include hydroperoxy derivatives of cholesteryl linoleate, linoleate, and cholesteryl hydroperoxides. Pretreatment of endothelial cells with ebselen, a synthetic glutathione peroxidase/phospholipid hydroperoxide glutathione peroxidase mimic, has been shown to afford protection against copper oxLDL (64). Scheme 1 summarizes the reactions of pro-apoptotic reactive oxygen and nitrogen species and the anti-apoptotic mechanism(s) of several antioxidants including ·NO.


View larger version (21K):
[in this window]
[in a new window]
 
Scheme 1.   A hypothetical model describing the inhibitory role of ·NO and other antioxidants in oxLDL-mediated apoptosis. Nitric oxide and antioxidants could inhibit apoptosis by chelating redox-active metal ions and by scavenging or decomposing reactive oxygen and nitrogen species at various points as indicated by the dotted arrow. The mechanism by which various agents inhibit cellular lipid oxidation and apoptsis is proposed as follows: DTPA and desferral (redox-metal ion chelation); PBN (trapping of lipid or lipid-derived peroxyl radical); BHT and probucol (scavenging of the lipid peroxyl radical); ebselen (decomposing lipid hydroperoxides and hydrogen peroxide); MnTBAP/FeTBAP (dismutating superoxide and hydrogen peroxide) and FeTBAP (decomposing peroxynitrite).

Based on the effects of PBN, ebselen, desferral, SOD mimetics, phenolic antioxidants, and ·NO donors as shown in the present study, we postulate that lipid peroxyl radicals trigger the apoptotic cascade (Scheme 1). This is linked to membrane lipid peroxidation which is presumably one of the earliest upstream apoptotic signaling events (65). Agents that inhibit this process are likely to negatively influence the apoptotic signaling process. Literature data also indicate that the metalloporphyrin class of SOD mimetics are efficient inhibitors of lipid peroxidation (66). The antioxidant effect of ·NO is linked to its ability to scavenge lipid peroxyl radicals (35, 36). Thus we propose that ·NO can potentially inhibit formation of intracellular reactive oxygen species. This antiapoptotic mechanism of ·NO will compete with the proapoptotic peroxynitrite-inducing reaction.

Extracellular and Intracellular ·NO Donors: Mechanism of Action-- In this study we used both intracellular and extracellular ·NO donors to investigate the antiapoptotic mechanism of ·NO. We used slow-releasing NONOates from which ·NO was released at defined rates with known stoichiometry from a thermolytic decomposition (53). The disadvantage of using extracellular NONOates is that a substantial proportion of ·NO generated extracellularly is oxidized before it enters the cell. As a result, we used relatively higher concentrations (~100 µM) of these compounds. In contrast, the advantage of using cell-permeable pro-·NO donors is that they require activation by cytoplasmic esterases in order to release ·NO. Consequently ·NO will be released intracellularly (see Scheme 2). Thus, relatively low concentrations (1-5 µM) of esterase-specific ·NO donors are needed for maximal results in apoptosis experiments.


View larger version (10K):
[in this window]
[in a new window]
 
Scheme 2.   Intracellular metabolism of pro-·NO donor by cytoplasmic esterases to an active ·NO donor.

Scavenging of Lipid Peroxyl Radical by ·NO: A Potential Antiapoptotic Mechanism?-- The collective works of our group (35, 52, 53) and other's (36, 67) have demonstrated the following: (i) ·NO is a highly sensitive inhibitor of copper- and azo-initiator-dependent LDL oxidation, (ii) ·NO outcompetes vitamin E as an inhibitor of LDL lipid oxidation, (iii) the release rate of ·NO from ·NO donors is a critical determinant of the extent of inhibition of lipid oxidation, (iv) ·NO inhibits cell-dependent LDL oxidation, and (v) ·NO inhibits the toxicity of oxLDL to endothelial cells by a peroxyl radical scavenging mechanism. The oxLDL itself is unreactive to ·NO. Published reports indicate that ·NO does not directly react with lipid hydroperoxides, aldehydes, or with other associated products of oxLDL, nor with beta -carotene and alpha -and gamma -tocopherols (68). ·NO, however, reacts with the lipid peroxyl radical associated with oxidizing LDL at a diffusion controlled rate (39). ·NO is a potent inhibitor of lipid peroxidation and LDL oxidation. Lipid peroxidation, the central process in most mechanisms of LDL modification, is controlled by the steady-state concentrations of lipid peroxyl radicals. Any compound that scavenges peroxyl radicals (e.g. alpha -tocopherol, Probucol) to give a stable end product will inhibit lipid peroxidation. The peroxyl radical can be thought of as an organic analog of superoxide in the same way that lipid hydroperoxide is an analog of hydrogen peroxide. Accordingly, the chemistry between ·NO and peroxyl radical is similar to that between ·NO and superoxide in that they react at a diffusion-limited rate through radical-radical recombination (38, 39). Differences occur due to the fact that the product of this reaction, unlike ONOO-, decomposes to stable products that do not re-initiate the peroxidation reaction. Because the endothelium and subendothelial space (the physiological locus of LDL modification) are exposed to a constant supply of ·NO due to basal NOS activity, these observations are of critical importance in determining the oxidative propensity of the artery wall. In addition, ·NO is a highly sensitive controller of cellular signaling processes that require lipid oxidation. Published data suggest that oxLDL exposure to endothelial cells impairs eNOS activation through displacement of eNOS from caveolae and attenuates the capacity of the endothelium to produce NO (69). Exposure of endothelial cells to oxLDL was shown to cause a decrease in the expression of eNOS (70). We propose that lipid peroxyl radicals or lipid hydroperoxides are responsible for initiating the apoptotic cell signaling and that this cascade of events is regulated by ·NO.

The increased formation of intracellular reactive oxygen species was suggested to be one of the mechanisms of endothelial apoptosis induced by oxLDL components (71). The intracellular source of ROS, however, remains to be established. OxLDL-induced cell membrane signaling leading to ROS generation is an active area of research. ROS can originate from endothelial nitric-oxide synthase, mitochondrial electron transport chain, xanthine oxidase, cyclooxygenase, and NADPH oxidases (72). Pritchard et al. (73), reported that endothelial cells incubated with atherogenic concentrations of native LDL released superoxide from eNOS. Wever et al. (41), also proposed an uncoupling of NOS activity as a mechanism of increased formation of superoxide and ONOO- under similar conditions. Clearly, the identification of the intracellular source of ROS in oxLDL-induced endothelial apoptosis will remain a challenging task in future studies.

In conclusion, we have shown that ·NO can effectively inhibit endothelial apoptosis mediated by oxLDL. It is likely that the antiapoptotic mechanism of ·NO is probably linked to its ability to scavenge the lipid peroxyl radicals that are presumably responsible for the apoptotic signaling cascade.

    ACKNOWLEDGEMENT

We thank Dr. Nalini Santanam, Emory University, for providing us with fresh LDL during the initial stages of this project.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL47250-09, HL63119, and RR01008.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Biophysics Research Institute, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee, WI 53226. Tel.: 414-456-4035; Fax: 414-456-6512; E-mail: balarama@mcw.edu.

Published, JBC Papers in Press, February 1, 2001, DOI 10.1074/jbc.M011731200

    ABBREVIATIONS

The abbreviations used are: oxLDL, oxidized low-density lipoprotein; TUNEL, terminal deoxynucleotidyltransferase-mediated nick-end labeling (assay); PBN, alpha -phenyl-tert-butylnitrone; BAEC, bovine aortic endothelial cells; NOS, nitric-oxide synthase; ·NO, nitric oxide; LDL, low density lipoprotein; DETA/NO, diethylenetriamine NONOate; GSNO, S-nitrosoglutathione; Hsp70, heat shock protein 70; BHT, butylated hydroxytoluene; TBAP, tetrakis(4-benzoic acid) porphyrin; Bcl-2, B-cell lymphoma-2 protein; MnTBAP, Mn(III) tetrakis-(4-benzoic acid)porphyrin; FeTBAP, Fe(III) tetrakis-(4-benzoic acid)porphyrin; 7-KC, 7-ketocholesterol; SOD, superoxide dismutase; DTPA, diethylenetriaminepentaacetic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L. (1989) N. Engl. J. Med. 320, 915-924[Medline] [Order article via Infotrieve]
2. Chisolm, G. M. I., II, Hazen, S. L., Fox, P. L., and Cathcart, M. K. (1999) J. Biol. Chem. 274, 25959-25962[Free Full Text]
3. Heinecke, J. W. (1998) Atherosclerosis 141, 1-15[CrossRef][Medline] [Order article via Infotrieve]
4. Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards, P. A., Watson, A. D., and Lusis, A. J. (1995) Circulation 91, 2488-2496[Abstract/Free Full Text]
5. Berliner, J. A., and Heinecke, J. W. (1996) Free Radic. Biol. Med. 20, 707-727[CrossRef][Medline] [Order article via Infotrieve]
6. Devaraj, S., and Jialal, I. (1996) Int. J. Clin. Lab. Res. 26, 178-184[Medline] [Order article via Infotrieve]
7. Steinbrecher, U. P., Zhang, H., and Lougheed, M. (1990) Free Radic. Biol. Med. 9, 155-168[Medline] [Order article via Infotrieve]
8. Hajjar, D. P., and Haberland, M. E. (1997) J. Biol. Chem. 272, 22975-22978[Free Full Text]
9. Heinecke, J. W., Rosen, H., and Chait, A. (1984) J. Clin. Invest. 74, 1890-1894[Medline] [Order article via Infotrieve]
10. Cathcart, M. K., Li, Q., and Chisolm, G. M. (1995) J Lipid Res. 36, 1857-1865[Abstract]
11. Smith, C., Mitchinson, M. J., Aruoma, O., and Halliwell, B. (1992) Biochem. J. 286, 901-905[Medline] [Order article via Infotrieve]
12. Darley-Usmar, V. M., Hogg, N., O'Leary, V., Wilson, M. T., and Moncada, S. (1992) Free Radic. Res. Commun. 17, 9-20[Medline] [Order article via Infotrieve]
13. Graham, A., Hogg, N., Kalyanaraman, B., O'Leary, V., Darley-Usmar, V., and Moncada, S. (1993) FEBS Lett. 330, 181-185[CrossRef][Medline] [Order article via Infotrieve]
14. Xing, X., Baffic, J., and Sparrow, C. P. (1998) J. Lipid Res. 39, 2201-2208[Abstract/Free Full Text]
15. Ehrenwald, E., Chisolm, G. M., and Fox, P. L. (1994) J. Clin. Invest. 93, 1493-1501[Medline] [Order article via Infotrieve]
16. Folcik, V. A., Nivar-Aristy, R. A., Krajewski, L. P., and Cathcart, M. K. (1995) J. Clin. Invest. 96, 504-510[Medline] [Order article via Infotrieve]
17. Parthasarathy, S., Wieland, E., and Steinberg, D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1046-1050[Abstract]
18. Sparrow, C. P., Parthasarathy, S., and Steinberg, D. (1988) J. Lipid Res. 29, 745-753[Abstract]
19. Cathcart, M. K., McNally, A. K., and Chisolm, G. M. (1991) J. Lipid Res. 82, 63-70
20. Kühn, H., Belkner, J., Zaiss, S., Fährenklemper, T., and Wohlfeil, S. (1994) J. Exp. Med. 179, 1903-1911[Abstract]
21. Steinberg, D. (1999) J. Clin. Invest. 103, 1487-1488[Free Full Text]
22. Hazen, S. L., and Heinecke, J. W. (1997) J. Clin. Invest. 99, 2075-2081[Abstract/Free Full Text]
23. Leeuwenburgh, C., Hardy, M. M., Hazen, S. L., Wagner, P., Oh-ishi, S., Steinbrecher, U. P., and Heinecke, J. W. (1997) J. Biol. Chem. 272, 1433-1436[Abstract/Free Full Text]
24. Podrez, E. A., Schmitt, D., Hoff, H. F., and Hazen, S. L. (1999) J. Clin. Invest. 103, 1547-1560[Abstract/Free Full Text]
25. Natarajan, R., Pei, H., Gu, J. L., Sarma, J. M., and Nadler, J. (1999) Cardiovasc. Res. 41, 489-499[CrossRef][Medline] [Order article via Infotrieve]
26. Haberland, M. E., Fong, D., and Cheng, L. (1988) Science 241, 215-218[Medline] [Order article via Infotrieve]
27. Seelos, C., Gmeiner, B., Kapiotis, S., and Cerni, C. (1997) Biochem. Mol. Biol. Int. 42, 1015-1022[Medline] [Order article via Infotrieve]
28. Dimmeler, S., Hermann, C., and Zeiher, A. M. (1998) Eur. Cytokine Network 9, 697-698[Medline] [Order article via Infotrieve]
29. Dimmeler, S., Rippmann, V., Weiland, U., Haendeler, J., and Zeiher, A. M. (1997) Circ. Res. 81, 970-976[Abstract/Free Full Text]
30. Haendeler, J., Weiland, U., Zeiher, A. M., and Dimmeler, S. (1997) Nitric Oxide 4, 282-293[CrossRef]
31. Vieira, O., Escargueil-Blanc, I., Meilhac, O., Basile, J. P., Laranjinha, J., Almedia, L., Salvayre, R., and Wegre-Salvayre, A. (1998) Br. J. Pharmacol. 123, 565-573[Abstract]
32. Dimmeler, S., Hermann, C., Galle, J., and Zeiher, A. M. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 656-664[Abstract/Free Full Text]
33. Jessup, W., Mohr, O. D., Gieseg, S. P., Dean, R. T., and Stocker, R. (1992) Biochim. Biophys. Acta 180, 73-82
34. Malo-Ranta, U., Yla-Herttuala, S., Metsa-Ketela, T., Jaakkola, O., Moilanen, E., Vuorinen, P., and Nikkari, T. (1994) FEBS Lett. 337, 179-183[CrossRef][Medline] [Order article via Infotrieve]
35. Hogg, N., Kalyanaraman, B., Joseph, J., Struck, A., and Parthasarathy, S. (1993) FEBS Lett. 334, 170-174[CrossRef][Medline] [Order article via Infotrieve]
36. Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaraman, B., Barnes, S., Kirk, M., and Freeman, B. A. (1994) J. Biol. Chem. 269, 26066-26075[Abstract/Free Full Text]
37. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1620-1624[Abstract]
38. Hui, R. E., and Padmaja, S. (1993) Free Radic. Res. Commun. 18, 195-199[Medline] [Order article via Infotrieve]
39. Padmaja, S., and Hui, R. E. (1993) Biochem. Biophys. Res. Commun. 195, 539-544[CrossRef][Medline] [Order article via Infotrieve]
40. Beckman, J. S., Ye, Y. Z., Anderson, P. G., Chein, J., Accavitti, M. A., Tarpey, M. M., and White, C. R. (1994) Biol. Chem. Hoppe-Seyler 375, 81-88[Medline] [Order article via Infotrieve]
41. Wever, R. M. F., Luscher, T. F., Cosentino, F., and Rabelink, T. J. (1998) Circulation 97, 108-112[Free Full Text]
42. Day, B. J., Shawen, S., Liochev, S. I., and Crapo, J. D. (1995) J. Pharmacol. Exp. Ther. 275, 1227-1232[Abstract]
43. Field, L., Dilts, R. V., Ravichandran, R., Lenhert, P. G., and Carnahan, G. E. (1978) J. Chem. Soc. Chem. Commun. 249-250
44. Hatch, F. T. (1968) Adv. Lipid Res. 6, 1-68[Medline] [Order article via Infotrieve]
45. Hamilton, R. J., and Hamilton, S. (eds) (1980) Lipid Analysis: A Practical Approach , IRC Press, Oxford
46. Kotamraju, S., Konorev, E. A., Joseph, B., and Kalyanaraman, B. (2000) J. Biol. Chem. 275, 33585-33592[Abstract/Free Full Text]
47. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
48. Sies, H., and Parnham, M. (2000) Expert Opin. Investig. Drugs. 9, 607-619[Medline] [Order article via Infotrieve]
49. Faulkner, K. M., Liochev, S. I., and Fridovich, I. (1994) J. Biol. Chem. 269, 23471-23476[Abstract/Free Full Text]
50. Lee, J., Hunt, J. A., and Groves, J. T. (1998) J. Am. Chem. Soc. 120, 7493-7501[CrossRef]
51. Konorev, E. A., Kennedy, M. C., and Kalyanaraman, B. (1999) Arch. Biochem. Biophys. 368, 421-428[CrossRef][Medline] [Order article via Infotrieve]
52. Struck, A. T., Hogg, N., Thomas, J. P., and Kalyanaraman, B. (1995) FEBS Lett. 361, 291-294[CrossRef][Medline] [Order article via Infotrieve]
53. Goss, S. P. A., Hogg, N., and Kalyanaraman, B. (1997) J. Biol. Chem. 272, 21647-21653[Abstract/Free Full Text]
54. Mannick, J. B., Hausladen, A., Liu, L., Hess, D. T., Zeng, M., Miao, Q. X., Kane, L. S., Gow, A. J., and Stamler, J. S. (1999) Science 284, 651-654[Abstract/Free Full Text]
55. Rossig, L., Fichtlscherer, B., Breitschopf, K., Haendeler, J., Zeiher, A. M., Mulsch, A., and Dimmeler, S. (1997) J. Biol. Chem. 274, 6823-6826[Abstract/Free Full Text]
56. Saavedra, J. E., Shami, P. J., Wang, L. Y., Davies, K. M., Booth, M. N., Citro, M. L., and Keefer, L. K. (2000) J. Med. Chem. 43, 261-269[CrossRef][Medline] [Order article via Infotrieve]
57. Nishio, E., Arimura, S., and Watanabe, Y. (1996) Biochem. Biophys. Res. Commun. 223, 413-418[CrossRef][Medline] [Order article via Infotrieve]
58. Lizard, G., Miguet, C., Bessede, G., Monier, S., Gueldry, S., Neel, D., and Gambert, P. (2000) Free Radic. Biol. Med. 28, 743-753[CrossRef][Medline] [Order article via Infotrieve]
59. Lizard, G., Deckert, V., Moisant, D. L., Gambert, P., and Larost, L. (1996) Am. J. Pathol. 148, 1625-1638[Abstract]
60. Kim, Y. M., deVera, M. E., Watkins, S. C., and Billar, T. R. (1997) J. Biol. Chem. 272, 1402-1411[Abstract/Free Full Text]
61. Li, C. Y., Lee, J. S., Ko, Y. G., Kim, J. I., and Seo, J. S. (2000) J. Biol. Chem. 275, 25665-25671[Abstract/Free Full Text]
62. Suschek, C. V., Krischel, V., Bruch-Gerharz, D., Berendji, D., Krutmann, J., Kroncke, K.-D., and Kolb-Bachofen, V. (1999) J. Biol. Chem. 274, 6130-6137[Abstract/Free Full Text]
63. Sata, M., and Walsh, K. (1998) J. Biol. Chem. 273, 33103-33106[Abstract/Free Full Text]
64. Thomas, J. P., Kalyanaraman, B., and Girotti, A. W. (1994) Arch. Biochem. Biophys. 315, 244-254[CrossRef][Medline] [Order article via Infotrieve]
65. Girotti, A. W. (1998) J. Lipid Res. 39, 1529-1542[Abstract/Free Full Text]
66. Patel, M., and Day, B. J. (1999) Trends Pharmacol. Sci. 20, 359-364[CrossRef][Medline] [Order article via Infotrieve]
67. O'Donnel, V. B., Chumley, P. H., Hog, H., Bloodsworth, A., Darley-Usmar, R. M., and Freeman, B. A. (1997) Biochemistry 36, 15216-15223[CrossRef][Medline] [Order article via Infotrieve]
68. Hogg, N., Singh, R. J., Goss, S. P. A., and Klyanaraman, B. (1996) Biochem. Biophys. Res. Commun. 224, 696-702[CrossRef][Medline] [Order article via Infotrieve]
69. Blair, A., Shaul, P. W., Yuhanna, I. S., Conrad, P. A., and Smart, E. J. (1999) J. Biol. Chem. 274, 32512-32519[Abstract/Free Full Text]
70. Liao, J. K., Shin, W. S., Lee, W. Y., and Clark, J. C. (1995) J. Biol. Chem. 270, 319-324[Abstract/Free Full Text]
71. Cominacini, L., Garbin, u., Pasini, A. F., Davoli, A., Campagnola, M., Pastorino, A. M., Gaviraghi, G., and Lo Cacio, V. (1998) J. Hypertens. 16, 1913-1919[CrossRef][Medline] [Order article via Infotrieve]
72. Carr, A. C., McCall, M. R., and Frei, B. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 1716-1723[Abstract/Free Full Text]
73. Pritchard, K. A., Jr., Groszek, L., Smalley, D. M., Sessa, W. C., Wu, M., Villalon, P., Wolin, M. S., and Stemmerman, M. B. (1995) Circ. Res. 77, 510-518[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.